Pfizer optimistic about drug candidates in late-stage development

04/2/2009 | Wall Street Journal, The · Reuters

In a periodic update, Pfizer presented a positive outlook for some of its drugs entering late-stage development, including a JAK inhibitor for rheumatoid arthritis, Alzheimer's disease drug Dimebon and Tanezumab, a monoclonal antibody to treat pain. In a separate announcement, the company said it is halting a trial of Sutent after the cancer medicine failed to outperform chemotherapy drug capecitabine in improving patients' condition.

View Full Article in:

Wall Street Journal, The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ